Evidence map›Paper›PMID 28919225›Full record

ArticleVaccine2018

A comparative cost analysis of the Vaccination Program for US-bound Refugees.

Heesoo Joo, Brian Maskery, Tarissa Mitchell, Andrew Leidner, Alexander Klosovsky, Michelle Weinberg

Open access · hybridAbstract readComparative Study
In one paragraph

Article in Vaccine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Heesoo JooDivision of Global Migration and Quarantine, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: hjoo@cdc.gov.
Brian MaskeryDivision of Global Migration and Quarantine, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Tarissa MitchellDivision of Global Migration and Quarantine, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Andrew LeidnerBerry Technology Solutions, Immunization Services Division, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Alexander KlosovskyInternational Organization for Migration, Washington D.C., USA.
Michelle WeinbergDivision of Global Migration and Quarantine, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Centers for Disease Control and Prevention · USMigration Policy Institute · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

backgroundVaccination Program for US-bound Refugees (VPR) currently provides one or two doses of some age-specific Advisory Committee on Immunization Practices (ACIP)-recommended vaccines to US-bound refugees prior to departure.

methodsWe quantified and compared the full vaccination costs for refugees using two scenarios: (1) the baseline of no VPR and (2) the current situation with VPR. Under the first scenario, refugees would be fully vaccinated after arrival in the United States. For the second scenario, refugees would receive one or two doses of selected vaccines before departure and complete the recommended vaccination schedule after arrival in the United States. We evaluated costs for the full vaccination schedule and for the subset of vaccines provided by VPR by four age-stratified groups; all costs were reported in 2015 US dollars. We performed one-way and probabilistic sensitivity analyses and break-even analyses to evaluate the robustness of results.

resultsVaccination costs with the VPR scenario were lower than costs of the scenario without the VPR for refugees in all examined age groups. Net cost savings per person associated with the VPR were ranged from $225.93 with estimated Refugee Medical Assistance (RMA) or Medicaid payments for domestic costs to $498.42 with estimated private sector payments. Limiting the analyses to only the vaccines included in VPR, the average costs per person were 56% less for the VPR scenario with RMA/Medicaid payments. Net cost savings with the VPR scenario were sensitive to inputs for vaccination costs, domestic vaccine coverage rates, and revaccination rates, but the VPR scenario was cost savings across a range of plausible parameter estimates.

conclusionsVPR is a cost-saving program that would also reduce the risk of refugees arriving while infected with a vaccine preventable disease.

Indexed as

Costs and Cost AnalysisRefugeesAdolescentAdultAgedAged, 80 and overChildChild, PreschoolFemaleHumansImmunization ProgramsInfantMaleMiddle AgedUnited StatesVaccinationVaccinesCost analysisOverseas vaccinationUS-bound refugees

Identifiers

PMID28919225
PMCPMC5851828
OpenAlexW2755008973

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.